Calliditas Therapeutics AB (publ) (CALT) Stock Forecast & Price Target

$40.00 0.00 (0.00%)

(As of 11/15/2024 ET)

Calliditas Therapeutics AB (publ) - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
5

Buy
0

Based on 5 Wall Street analysts who have issued ratings for Calliditas Therapeutics AB (publ) in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 5 have given a hold rating for CALT.

Consensus Price Target

$39.25
-1.88% Downside

According to the 5 analysts' twelve-month price targets for Calliditas Therapeutics AB (publ), the average price target is $39.25. The highest price target for CALT is $40.00, while the lowest price target for CALT is $39.00. The average price target represents a forecasted downside of -1.88% from the current price of $40.00.

Get the Latest News and Ratings for CALT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and its competitors.

CALT Analyst Ratings Over Time

Type	Current Forecast 11/18/23 to 11/17/24	1 Month Ago 10/19/23 to 10/18/24	3 Months Ago 8/20/23 to 8/19/24	1 Year Ago 11/18/22 to 11/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$39.25	$39.25	$39.25	$49.00
Forecasted Upside	-1.88% Downside	-1.88% Downside	N/A	183.40% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

CALT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CALT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Calliditas Therapeutics AB (publ) Stock vs. The Competition

Type	Calliditas Therapeutics AB (publ)	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-1.88% Downside	28,563.29% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent CALT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/31/2024	Citigroup 3 of 5 stars		Reiterated Rating	Buy ➝ Neutral	$39.00	-1.27%
5/28/2024	Lifesci Capital 2 of 5 stars	R. Katkhuda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2024	Jefferies Financial Group 2 of 5 stars		Reiterated Rating	Buy ➝ Hold	$58.00 ➝ $39.00	+2.77%
5/28/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$55.00 ➝ $40.00	+5.51%
5/28/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. He Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$39.00	+2.23%
8/18/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$21.00 ➝ $18.00	+8.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:36 AM ET.

CALT Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Calliditas Therapeutics AB (publ) is $39.25, with a high forecast of $40.00 and a low forecast of $39.00.
: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CALT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALT, but not buy additional shares or sell existing shares.
: According to analysts, Calliditas Therapeutics AB (publ)'s stock has a predicted downside of -1.88% based on their 12-month stock forecasts.
: Analysts like Calliditas Therapeutics AB (publ) less than other "medical" companies. The consensus rating for Calliditas Therapeutics AB (publ) is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CALT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!

This page (NASDAQ:CALT) was last updated on 11/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Stock Forecast & Price Target